Accium BioSciences
Developer of an ultrasensitive detection platform designed to overcome challenges faced in clinical development of novel drugs. The company's ultrasensitive detection platform investigates pharmacologic and pharmacodynamic endpoints of Merck's Temodar® in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-Temodar® administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients, enabling clinicians to involve therapeutic response prediction and resistance to treatment.
Domain
acciumbio.org
Country
United StatesIndustry
BiotechnologyEmployees
1-10
Last Funding
$3.0M
Founded
2004
Tech Stack (4 technologies)
Frequently Asked Questions
What technologies does Accium BioSciences use?+
Accium BioSciences uses 4 technologies including jQuery, Cloudflare, Google Font API.
What industry is Accium BioSciences in?+
Accium BioSciences operates in the Biotechnology industry.
Where is Accium BioSciences based?+
Accium BioSciences is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026